Endocrine Abstracts

Introduction/Background: 16th May 2024 NICE confirmed use of Selective Internal Radiation Therapy (SIRT) for neuroendocrine tumours that have metastasised to the liver, with arrangements in place for clinical governance, consent and audit. This was subject to Commissioners/providers implementing the guidance. Trans Arterial Embolisation (TAE) and Trans Arterial Chemo Embolisation (TACE) are two of the comparative therapies that the committee examined to come...

Introduction The diagnosis of carcinoid heart disease (CHD) is often made late and the patients are often deconditioned, with symptoms of fatigue, weight loss and refractory carcinoid symptoms. The challenge is then to improve the patient's condition by an enhanced pathway of prehabilitation and interventions, in order to consider surgical and medical therapies that can improve the patient's quality of life and prognosis. In 2018 due to the complexity of patients and increased...

Introduction: The Birmingham Neuroendocrine Tumour (NET) and Carcinoid Heart Disease( CHD) services evolved into a combined and bespoke specialist service in 2018, with the introduction of the enhanced CHD pathway. This involved discussion at the CHD NET MDT , CHD work-up in the inpatient or outpatient setting and a clinical review in the bespoke CHD NET clinic. The CHD NET pathway is now embedded and well-established at our centre. We have a consistent flow o...